STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more
By
Ed Silverman
Source
STATSTAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and morestatnews.comYou might also wanna read

Anthropic releases Claude Science, a product aimed at researchers, the pharma industry

Anthropic launches Claude Science AI workbench for biotech and pharma researchers
Anthropic announced Claude Science, an AI workbench for scientists that consolidates fragmented tools and datasets into a single environment

Anthropic launches Claude Science AI workbench for biotech and pharma researchers
Anthropic announced Claude Science, an AI workbench for scientists that consolidates fragmented tools and datasets into a single environment
Anthropic launches AI tool to speed up drug discovery
Anthropic's Claude AI Advances Scientific Research Through Life Sciences Specialization
Anthropic has developed Claude for Life Sciences, a specialized AI tool designed to accelerate scientific research and discovery. The compan
Anthropic launches Claude Science, a new AI product focused on life sciences research
Anthropic has launched "Claude Science," a new flagship product focused on AI applications in life sciences and scientific research. The pro
Anthropic launches Claude Science, a new AI product focused on life sciences research
Anthropic has launched "Claude Science," a new flagship product focused on AI applications in life sciences and scientific research. The pro
Anthropic launches Claude Science, a new AI product focused on life sciences research
Anthropic has launched "Claude Science," a new flagship product focused on AI applications in life sciences and scientific research. The pro
Anthropic Launches Claude Science Platform, Entering AI Drug Discovery Race Against DeepMind and OpenAI
Anthropic launched Claude Science, a beta research platform for life scientists, on June 30, 2026. This move completes a three-way competiti
awesomeagents.ai·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.